PSTV Stock Analysis
PS
Uncovered
Plus Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company develops a targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. Its lead radiotherapeutic candidate, Rhenium (186Re) obisbemeda is designed specifically to CNS cancers including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. The Company’s portfolio also includes 188RNL-BAM, a radioembolization therapy for liver cancer.